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ABSTRACT:
The costs for FDA approval are considered research and
development costs. The FASB has never mentioned FDA approval costs
in their pronouncements and therefore the method of treatment for
these costs was uncertain. The purpose of this paper is to
determine what the treatment of FDA approval costs should be and if
that method is consistent with the treatment of research and
development expenses. The main concern being whether to expense
the costs or capitalize the costs as assets. The accounting rules
were examined regarding research and development costs, and the
definition of FDA costs was determined. Data from companies who
incur research, development, and FDA costs was examined to
determine what type of treatment they used. After gathering this
information, I combined and compared it to determine that the most
cornmon, if not only treatment method used by the companies was to
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INTRODUCTION
The purpose of this project is to examine the costs associated
with the FDA approval process and to determine if such costs meet
the criteria of capitalized research and development costs. under
normal circumstances all research and development cost are treated
as expenses when incurred. There is an exception to this rule
which allows costs to be capitalized if they meet certain
requirements. I will explore this area and these requirements to
determine if FDA approval costs can be capitalized.
The reason for examining this topic is because often companies
are frustrated by expensing all the costs incurred through research
and development along with the millions of dollars spent each year
on FDA approval. They would prefer to practice the matching
principle which states that expenses should be matched with
revenues. This would make their company look more profitable by
avoiding such large expenses on the income statements until they
incur revenues to offset their expenses.
This topic has never been addressed in any articles or books
as far as I know. I find it interesting to examine a topic for
which there is no one correct answer at this time. It's a topic
that many people probably don't consider unless they are in a
specific industry that requires FDA approval.
The remainder of this paper will contain the following
sections. I will begin by describing the background information
related to this topic. In this section I will give detailed
explanations of what FDA costs are, what the accounting rules
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officially state, and why this is an accounting issue. I will also
describe articles that relate to these topics along with company
examples from their financial statements.
The next section will examine the different alternati ves
regarding FDA costs. I will consider whether the reporting options
are in accordance with the Financial Accounting Standards
Board(FASB)'s willpronouncements. alsoI state other
professionals' opinions and agree with or refute them.
The last section will consist of recommendations made by
myself and other professionals. I will also explain the effect the
recommendations will have on companies who incur FDA approval
costs.
BACKGROUND
RESEARCH AND DEVELOPMENT COSTS
In October 1974, the Financial Accounting Standards Board
(FASB) issued a Statement of Financial Accounting Standards No.2,
"Accounting for Research and Development Costs." This is the
accounting rule that still exists presently which states that "all
research and development costs must be expensed when incurred and
the expected value of R&D is zero." (Bierman 48) The exception to
this rule is when definite future benefits can be defined, then and
only then can they capitalize research and development. This
accounting treatment caused an uproar among many professionals
along with many companies who spend millions of dollars on research
and development every year. Prior treatment of research and
development costs allowed more capitalization along with giving
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value to research and development.
The FASB 's definition of research and development is as
follows:
Research is planned search or critical investigation aimed at
discovery of new knowledge with the hope that such knowledge will
be useful in developing a new product or service, a new process or
technique, or in bringing about a significant improvement to an
existing product or process. (Keiso & Weygandt 607)
Development is the translation of research findings or other
knowledge into a plan or design for a new product or process or for
a significant improvement to an existing product or process whether
intended for sale or use.(Kieso & Weygandt 607) For specific
examples of what costs can be included in research and development
costs and which costs must be excluded, see Appendix A.
ACCOUNTING ISSUE
After making the 1974 decision regarding the expensing of
research and development costs, the FASB offered the following
considerations supporting their decision: "1) Uncertainty of future
benefits; 2) Lack of causal relationship between expenditures and
benefits; 3) R&D does not meet the accounting concept of an asset;
4) Matching of revenues and expenses; and 5) Relevance of resulting
information for investment and credit decisions. "(Bierman 48)
One consideration in favor of expensing research and
development costs is the uncertainty of future benefits. This view
is fairly easy to understand. Many companies begin research
projects without knowing whether they are going to succeed or fail
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because there is always a high degree of risk involved. It is
difficult to determine what the project will be worth several years
in the future, if it will be worth anything at all. There is a
concept of uncertainty surrounding research and development costs.
It's just the nature of this area. On the other hand, the idea of
management planning should be considered because management does
not want to invest in a project they think will fail. Most
companies apply many hours to investment decisions involving
research and development along with weighing the costs and benefits
involved. Therefore, management engages in research and
development with the expectation that future benefits will result.
Many argue that the future benefits should be recorded as an asset.
The second factor cited by the FASB is the lack of causal
relation between expenditures and benefits. In this case the board
implies that there is no relationship between the expenditures for
research and development and the subsequent benefits received from
research and development. The FASB studies found this case to be
true, but several other studies, along with other discipline
theories such as economics, have proven false many economic studies
performed. It's been concluded that considerable research in the
business world does produce benefits to the firm. "Expenditures on
R&D to develop new products or improve old ones are likely to be
less correlated with market returns than expenditures for expansion
into new markets or expanding market capacity."(Bierman 52)
Basically, it depends on which view is taken when looking at the
relationship.
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Third, the FASB believes that research and development costs
do not meet the definition of an asset. The FASB defines an asset
as probable future economic benefits obtained or controlled by a
particular entity as a result of past transactions or events
(Bierman 53). They do not believe research and development costs
meet the definition of an asset because research and development
costs "future economic benefits cannot be identified and
objectively measured." (Bierman 53) This is also the reason
against capitalization. If it's not an asset, it cannot be
capitalized.
Fourth, the issue is the matching of expense and revenue. The
FASB uses the matching principle "in favor of expensing R&D."
(Bierman 53) Bierman and Duke's opinion of this argument is
similar to everyone else's. They argue that "the only reason R&D
expenditures are made is to benefit future time periods by
generating new revenues in those time periods." They also argue
that "the expensing of R&D consistent with matching is a conclusion
that is difficult to comprehend and goes against a basic principle
of accounting standards - the matching principle." (Bierman 53)
This illustrates that the matching principle can be utilized for
both sides of the argument.
Finally, the last factor the FASB cited as support is the
relevance of resulting information for investment and credit
decisions. ( Bierman 53) The FASB suggests that there is no
purpose in allocating these expenses throughout several periods.
They also state that "the capitalization of research and
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development costs is not useful in assessment of the earnings
potential of the enterprise." (Bierman 53) The FASB translates
this to mean that capitalizing research and development costs would
not make a substantial difference to investors who use the
financial statements. Dukes performed tests relating to the amount
of reliance placed on the financial statements regarding research
and development costs. He found that there were relationships
between research and development costs and the prediction of the
future return of a security. His opinion is that when research and
development cost are capitalized, it helps an investor predict a
return because the investor is aware of possible new discoveries
that would increase the value of a company. Research and
development costs can be a major expense of a company and can
largely affect the financial statements and the earnings per share
amount. Tests show that when research and development costs are
capitalized, it more accurately reflects the earnings per share
than if these costs were expensed.
All the above factors are presented as justification of the
FASB's decision to expense research and development costs as
opposed to capitalization. The opinion of Bierman and Dukes is
that this rule is not based on sound accounting theory but rather
is intended to avoid criticism and conflict when the benefit from
research and development is determined to be less than the cost
outlay. (Bierman 54). Overall, the problem is difficult to solve
since determining the future benefits from research and development
can be very difficult, if not impossible. The FASB attempts to be
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conservative yet, at the same time, is hurting many companies who
incur large amounts of expense.
ARTICLES
There have been numerous written opinions regarding the topic
of expensing research and developments costs. The bulk of opinions
oppose this accounting rule mainly because it violates the matching
principle.
In Roula Khalaf's article "Fuzzy Accounting" he states that
"the debate whether to expense or defer costs is one of the biggest
in accounting."(96) He agrees that the main problem with this
accounting rule is that the matching principle is not followed. He
also thinks that the rules regarding capitalization are not well-
defined. The translation of this opinion is that there needs to be
more structure surrounding capitalization rules instead of only
stating that those costs which provide economic future benefits can
be capitalized. If the rules are more clearly defined, there may
be less opposition to the expensing of research and development
costs.
This point of view is also shared by Maurice S. Newman in his
article "Accounting for Research and Development." His opinion is
that the current accounting rule regarding research and development
costs violates the matching principle. He feels that this rule has
been influenced too much by the Congress and the Internal Revenue
Service(IRS). He also understands that it is impossible to find a
"simple formula" for research and development because there is a
wide variation in the amount of research and development costs
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incurred in different industries. For example, the pharmaceutical
industry spends the most money on research and development often
exceeding billions of dollars. His conclusion is that the FASB
should reconsider its pronouncement on research and development
expenses. This is the conclusion shared by many individuals both
inside and outside the accounting field.
Lynn W. Ellis and Robert G. McDonald express a similar, yet
slightly different, opinion about research and development costs.
In their article "Reforming Management Accounting to Support
Today's Technology" they state that research and development
expenses should be considered part of the product cost. Research
and development usually makes up a major portion of the product
cost. If research and development is not included in product cost,
it provides an inaccurate estimate of what the product actually
costs to manufacture.
A good point made by Ellis and McDonald is that "growth-
enhancing activities such as R&D, market development and
manufacturing development, are treated as expenses to be minimized
rather than as investments in the future."(31) This is central
idea in the area of research and development expenses. It's
"research and development that drives the economy." (Newman 6) If
research and development is not encouraged no new products will be
developed, the rate of technology change will decrease, and the
economy and companies will suffer. It is also essential to
consumer's well-being to encourage research and development,
especially in the pharmaceutical industry. Having companies
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expense all research and development costs does not encourage them
to incur research and development costs. This treatment of
research and development cost could prevent the discovery of vital
drugs/products that may save people from serious diseases or other
problems.
The Ellis and McDonald article also mentioned the violation of
the matching principle and how there is now less disclosure in
research and development endeavors. They share the opinion of
others that feel research and development costs need a detailed
analysis keeping in mind those businesses who incur excessive
research and development costs.
A final viewpoint is that of David E. Nix and Paul E. Nix in
their article "It's Time to Change the Financial Accounting
Treatment of R&D Expenditures." Once again they follow the
opinions of the others stated above. They believe that the
accounting treatment is obsolete and that new methods should be
developed. They concur with the others' opinion that the matching
principle is violated by the FASB ignoring sound accounting theory.
They go on to state that the United States is at a competitive
disadvantage because of their treatment of research and development
since many other countries, such as Australia and Canada, are
allowed to defer their research and development expenses.
The difference in this article from all the others is that
they offer an alternati ve approach. This approach involves placing
all research and development expenses incurred into a contra
stockholder's equity account instead of expensing the costs. This
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approach looks more at the long-term expenses because research and
development projects almost always last more than one year. This
approach will be discussed more thoroughly later.
All the articles cited basically express the same view point
that the accounting rules need to be changed. This is the main
area of conflict surrounding research and development costs. It
seems as if the majority of people do not side with the FASB on
this issue.
My conclusions from the analysis of these articles leads me to
believe that there are some definite misunderstandings between the
FASB and accountants in general. The main area is with the
matching principle. The matching principle is defined as the
expense recognition that is tied to revenue recognition. The
expenses should be matched with revenue whenever it is reasonable
and practical to do so. It also goes on to say that this type of
expense recognition pattern involves assumptions about the benefits
that are being received as well as the costs associated with those
benefits. Also, some costs are charged to expense in the current
period simply because no confection with revenue can be determined.
(Kieso & Weygandt 607-8)
This definition clearly explains why the FASB is able to
advocate their research and development costs treatment. The
clause about no connection between the costs and benefits partially
supports the FASB' s opinion and the opposition's opinion. There is
no connection currently but in the long-term outlook there is a
connection.
10
research and development expenses, and finally analyzing if these
costs can be capitalized or expensed.
First we must look at the FDA's purpose. The Food & Drug
The other clause that the FASB seems to use to support its
opinion are the words "reasonable and practical." The FASB does
not support the view that capitalizing research and development is
reasonable and practice. Their opinion is that capitalizing
research and development costs causes more harm then good and its
only fair to have one standard way of handling these costs.
FDA APPROVAL COSTS
The next area of investigation is the definition of FDA approval
costs. This includes describing the purpose of the FDA, defining
FDA costs, determining if these costs meet the qualifications for
Administration(FDA) is a "scientific regulatory Agency responsible
for the safety of the Nation's foods, cosmetics, drugs, medical
devices, biologics, and electronic radiological products.
"
(Campbell
3) The federal government controls this Agency whose main purpose
is for public interest, that being safety and welfare. The FDA
"monitors the industry and provides the consumer the best
assurances possible itsindustrythat isthe meeting
responsibility" (Campbell 3), the industry's responsibility being to
make sure their products are safe. It is important to understand
that the FDA is not responsible for creating safe products, but
only to test and monitor products to be confident that they are
harmless. For many of these products it is required that they






































(9.75 years) (5.5 years) (4.25 years)
a Investigational New Drug. b New Drug Application.
(Ember, Lois C&EN November 25, 1991 page 4)
Each of the phases contain numerous procedures which all
require a large amount of time and capital. There has been a
recent push to speed up the approval process for new
drugs/products. Unfortunately, along with the speedy process comes
an increase in costs. The cost of getting a new drug/product to
the market can range from at least $150 million to several billion
dollars depending on the type of research findings needed and the
risks involved.
The procedures for each step of the FDA approval process are
as follows(as related to drug approvals):
--Preclinical Testing: This step includes analyzing the
drug/products's composition and the first stages of animal testing.
The worthiness of human testing must be determined.
--IND Approval: The new drug is preliminary approved for human
clinical trials. In order to get approval for clinical testing,
the company must show: 1)the protection of the human research
subject, 2)the adequacy of animal studies already completed, 3)the
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scientific merits of the research plan, 4)the qualifications of the
investigator. (Lucas 80)
-- IND Phase I : This phase includes profiling the safety and
pharmacological acti vi ty of a drug. These procedures are performed
on a small number of healthy volunteers(non-patients). This stage
determines what constitutes a safe dosage, how long the effects of
the drug last, and the way the drug is absorbed, distributed,
metabolized, and excreted. The situations in this phase are highly
controlled.
--IND Phase II: This stage begins the efficacy tests on patients,
which are "tests providing that a drug is ineffective as it is
purported to be, without harmful or disagreeable side effects,
safety being stressed." (Grabowski 22) These test are conducted on
volunteer patients, approximately between 200-300 patients. Animal
and human studies for safety are performed coincidently.
--IND Phase III: This stage is usually the most extensive of all
the trials. The goal in this stage is to confirm the efficacy
results from Phase II in patients afflicted with the specific
disease. Further, they identify low-incidence adverse effects.
--NDA Preparation Time: This step includes gathering all the data
from the pre-clinical and clinical studies along with information
about the chemical structure, scientific rationale and purpose, and
formulation and manufacturing details. This application is usually
thousands of pages long.
--FDA Approval Process: This step includes a final review and
analysis from all the information included in the New Drug
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Application(NDA). It is at this stage that the final
approval/disapproval is given. The FDA uses a team approach to
review the application.
(The above information adapted from C&EN February 25, 1991 page 30)
As mentioned above there has been a move towards decreasing
the time needed to approve new drugs/products, especially those
drugs which are used to treat life-threatening illnesses. For
life-threatening illnesses, the FDA will allow the drug to be used
for treatment as long as it is in the marketing approval stage. In
conjunction with this situation to the decrease in approval time is
the adoption of user fees. User fees are additional fees added on
to various stages in the FDA approval process. The reason for the
adoption of this bill is that "traditional sources of funding are
no longer enough to do with reasonable speed the job that needs to
be done."(Hanson 6) With the additional funds the FDA will be
receiving, they will be able to hire additional scientists,
physicians, and administrative staff. This means the approval
process time will be reduced because there are more professionals.
The new staff will help to reduce the current workload which is
already somewhat overbearing and prepare for the future which
predicts an increase in the number of product applications.
As of the end of 1992, the user fees were apportioned as
follows: 1) $150,000 for each new drug application, 2) $50,000 for
each drug company annually, and 3) $5,000 for each product a
company has on the market. These amounts are to be phased in over
a five-year period beginning in 1993 and will bring in revenues to
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the FDA totaling approximately $75 million per year. (Adapted from
Hanson 6-7) This may pose a problem for the smaller companies who
are unable to afford such high costs when they are already
performing costly research methods. The federal government is
looking at allowing smaller companies to defer these fees up to one
year after gaining approval which will allow for the companies to
recognize some income.
FDA COSTS AS RESEARCH AND DEVELOPMENT
The next area regarding FDA approval costs is whether they are
considered research and development costs. First we must refer to
the definition of research and development. According to this
definition, and looking at the list of what constitutes research
and development activities, it is easy to determine that the seven
FDA approval stages are considered research and development. The
definition of research says that it is an investigation that hopes
to discover useful knowledge to bring about an improvement.
Development is the translation of research findings into knowledge
for a new product intended for use. These definitions are what FDA
costs accomplish. FDA approval seeks to gain new knowledge about
a product that is being developed and make sure that the product is
safe for the market. There is much research involved in FDA
approval as explained above. Therefore, from the definitions it
can be assumed that FDA costs are considered part of research and
development costs.
The activities I am referring to that relate to research and
development are "1) testing in search for or evaluation of product
16
Nothing in the definition of research and
development or in the listing of research and development
activities relates to straight fees charged by an agency.
or process alternatives, 2) laboratory research aimed at discovery
of new knowledge, and 3) conceptual formulation and design of
possible product or process alternatives."(Kieso & Weygandt 607-
608) All these research and development activities are what is
performed during the stages of FDA approval, so therefore the costs
from these stages are classified as research and development costs.
The second set of costs to analyze are the newly-proposed user
fees. These fees are administrative in nature because accompany
paperwork procedures.
Therefore these costs are not considered research and development
costs and are expensed as administrative costs when incurred.
The final area to analyze for FDA costs is whether they should
be expensed or capitalized. No articles have been published
specifically on this issue which makes it difficult to determine
exactly what the FASB's opinion would be on this matter although,
the FASB's opinion on research and development costs was stated
earlier. This discussion relates to the explanation of when
research and development costs can be capitalized which leads to
the attempt to specify definite future benefits. This topic will
be discussed later along with the different alternatives relating
to the options of capitalization or expensing.
COMPANY DATA
The third and background section brings in specific examples
of the treatment of FDA approval costs by various companies. When
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looking at the companies for which I have collected data, the
general consensus seems to be expensing of research and development
costs along with the costs associated with FDA approval. The data
collected is from financial statements, notes to the financial
statements, and managers notes.
I took a sample of fifteen financial statements from companies
that have extensive research and development costs and are also
experiencing an increase in FDA approval costs. Insertions from
the companies financial statements are found in Appendix C. I will
refer to a few that have significant information.
The first company to be investigated is Houston Biotechnology
Inc. This company "engages in the development of pharmaceutical
products to treat or prevent a variety of common ophthalmic and
neurological diseases and disorders. "(Financial Footnotes) Their
products involve a high degree of risk and uncertainty and
therefore require a large investment in cash and technical
resources before the product can enter the commercial market.
Commercialization requires FDA approval on the products which can
take many years. Because of the risk and uncertainty, Houston
Biotechnology Inc. will not realize its research and development
investment until the FDA gives approval to market the drug and
profi ts are generated at a future date. Therefore, since this
company does not measure or realize an investment until the product
is approved for market, they expense all research and development
costs when incurred, including FDA approval costs.
The second company is Pharmaceutical Resources Inc. This
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company primarily genericmanufactures and distributes
pharmaceuticals, mainly the oral solid form(tablet and capsule).
At their financial statement date, they were waiting for FDA
approval on one product line. The FDA insisted that they avoid
submitting any more new drug applications until the FDA has a
chance to perform a validity assessment program on those current
products waiting FDA approval. Because a management is unable to
predict what the outcomes of this program will have on the product
lines or operations in general, they expense all costs when they
are incurred. As the definition of research and development costs
states, Pharmaceutical Resources Inc.' s costs must be expensed
since they are unable to define the value of the benefits they may
receive.
The third and company is Helix Biocore, Inc. This company
operates in the cardiovascular field, more specifically the
production and development of heart valves. The unusual aspect of
this company is that they are able to give a definite estimate of
future benefits. They state in their 1992 financial statements:
"today, estimates are that the world market for heart valves is
$410 million." They go on to state that the United States market
will be limited at first because they still must obtain FDA
approval. Helix Biocore, Inc. decided to expense all their
research and development costs as incurred, even though they would
have a valid argument if they wanted to capitalized their costs.
I feel that the reason they expense their costs is because it's the
norm to treat research and development costs in that manner, and
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also because they must still obtain FDA approval in the United
States. Since the costs of FDA approval are enormous and difficult
to estimate, it was easier to expense all the costs associated with
research and development.
After reviewing my sample of financial statements, I reached
the conclusion that all the companies I looked at expensed their
research and development costs, which includes their FDA approval
costs. The most commonly stated reasons were the inability to
measure the possible future benefits of their research and
development investments and to determine if their product will
receive FDA approval. Appendix B recaps the conclusions of the
financial statements. It shows the reasons the companies give for
their treatment of research, development, and FDA costs, and what
their treatment is for research, development, and FDA costs.
The next section of the paper will consider the reporting
alternatives.
ALTERNATIVES
There are two alternative as to the treatment of research and
development costs mainly the costs of FDA approval. One
alternative is to treat research, development, and FDA approval
costs as expenses. The other alternative is to treat these costs
as assets and capitalize the costs over a number of years. The
FASB's definition of research and development costs is narrow
meaning it does not allow many companies to treat the research and
development costs as assets, when actually these costs often become
revenue-producing assets. The FASB makes no mention of FDA
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approval costs; it never addresses the issue. It is the companies
and accountants responsibility to determine if these FDA approval
costs can be considered assets or expenses.
EXPENSES
The majority, if not all, the companies(especially the
companies I reviewed) treated their research and development costs
as expenses. They included their costs of FDA approval in the
research and development category which is appropriate because FDA
approval costs are considered the "final end" of research and
development costs. The question is why do all the companies choose
to expense the enormous costs associated with FDA approval when the
treatment of these costs as assets would be more beneficial to the
company? The answer is the rules and guidelines set by the FASB.
As mentioned in the background section, the FASB's reasons for
treating the majority of research and development costs as expenses
were stated, along with the strict opposition to this treatment of
costs. The five reasons stated again are: "1) Uncertainty of
future benefits; 2) Lack of causal r e 1 at ion s hip between
expendi tures and benefits; 3) R&D does not meet the accounting
concept of an asset; 4) Matching of revenues and expenses; 5 )
Relevance of resulting information for investment and credit
decisions." (Bierman 48) Because it was previously determined that
FDA approval costs are considered part of research and development
costs, the FASB guidelines also apply to FDA approval costs. All
the reasons are applicable in this situation. It is difficult to
determine if a company's product will be approved, much less to
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determine what the expected benefit will be. It is easier to see
the relationship between FDA approval costs and benefits. Many
drugs cannot be marketed unless they receive FDA approval,
therefore the expenditures provide a benefit, although if the drug
is not approved, there is no relationship. This information gives
a good reason why these costs should be treated as expenses.
Another important factor why FDA costs should be expensed is
conservatism. When dealing with FDA costs, a company cannot be
certain that they will receive FDA approval much less when they
will receive that approval. This involves a great deal of
uncertainty. It is safe and more conservative to give the expected
value of research, development, and FDA costs a value of zero,
thereby expensing all the costs they incur. (Bierman 48) This
treatment avoids making many adjustments if the FDA doesn't approve
the product or the research and development does not produce any
revenues.
One area of FDA costs that should always be considered
expenses are the newly adopted user fees. These costs are
administrative in nature because they are costs attached to the use
of facilities and applications. They are a set amount and are the
same for every product no matter how long the approval process
lasts nor how much money the company has. Because these costs are
not considered part of the definition of research and development,
and therefore not part of the definition of FDA approval costs,
they will always be treated as expenses and separated from the
other FDA costs.
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expensed or why it would be beneficial to expense the costs. It
seems to be the alternative most companies tend to follow.
ASSETS
Expensing FDA costs is not only more conservative, it is also
simpler to apply. There is no need to calculate and determine
amortization amounts. The FASB only requires brief disclosure
regarding research and development expenses, including FDA
expenses. The disclosure could be as brief as one line on the
income statement listing research and development expenses for the
year to paragraphs explaining what the research, development, and
FDA costs are for and what they consist of.
The previous factors are the reasons why FDA costs should be
The other alternative is that of treating FDA costs as assets,
which is the least common alternative. Many opinions back this
alternative because it seems to be the better approach for
companies to follow.
The reason most commonly stated in accordance with the asset
alternative is that of the matching principle. Once again, the
matching principle states that expenses should be matched against
the revenues in the period the revenues are earned. In the case of
FDA approval costs, this could be a time period of over ten years.
Maurice S. Newman states "in an accounting sense, assets are
created and these costs should be matched against future revenues
when the R&D brings forth fruit." (Newman 6) The same could be
said for FDA costs. FDA costs produce assets if the FDA approves
the product. The revenues produced by products with FDA approval
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cannot be offset by expenses of the products because the expenses
were incurred probably many years before and have already been
removed from the income statement.
Related to the matching principle is the length of time and
the amount of cash investment required for FDA approval. In 1991,
it took an average of three years for the FDA to approve a drug
(FDA approval stage - one of the last phases), and it took an
average of twelve years to get the drug from the lab to the market.
(Hanson 28) The amount of cash investment needed to gain FDA
approval begins at $125 million and quickly increases, the average
being around $400 million for one product. It was said that in
order to compete the pharmaceutical industry will invest
approximately $8 billion. (Ember 6) This is a long time and an
enormous amount of money to expense every year. It would make more
sense to capitalize the costs and spread they out evenly over the
life of the product. If in the future it is determined that the
there were more cost than revenues, then expense the excess costs.
Ellis and McDonald have an opinion that says
"a consequence of
this erroneous focus is that growth-enhancing activities such as
R&D, market development, and manufacturing development, are treated
as expenses to be minimized rather than investments in the future."
(Ellis 31) They make a valid point about the economics of product
development. We as consumers want companies to develop new and
better products to increase our quality of life. We would also
prefer that the costs be kept down so all consumers could share in
the new technology. When companies have to expense all their
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costs, these costs are passed on to the consumer, whereas if they
were capitalized the companies would have less expenses and
therefore less costs to the consumers. This statement is not
saying that all projects should be considered valid and be
capitalized, yet it is implying that projects be analyzed more
closely to determine if they have a good chance of being approved
by the FDA. If the product does have a good chance of approval,
then determine if the product will be profitable in the
marketplace. If this favorable outcome can be concluded from the
current company information, the product costs, especially those
relating to FDA approval, should be capitalized. If the product is
terminated before it is placed on the market or before FDA
approval, then all the costs can be expensed.
More disclosure is required for treating FDA approval costs as
assets. In the financial statements a company must show the value
of the asset and the amount that has been capitalized. In the
notes to the financial statements a company must show the
capitalization schedule and give a detailed description of the
asset being capitalized. FDA approval could be considered an asset
because it most often provides for future economic benefit. If a
product gains FDA approval, it is almost 100 percent certain that
the product will be marketed.
The previous paragraphs gave reasons in favor of treating FDA
approval costs as assets. It is probably the most practical
solution for most companies to adopt. Unfortunately it is also the
least common approach to utilize.
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As can be determined from the arguments stated above, there is
a thin line between treating FDA approval costs as expenses or
assets. Just because one method is more common does not mean that
the method is the best for that company. Which alternati ve a
company uses usually depends on how they fit the FASB's guidelines
for research and development costs.
RECOMMENDATIONS
In my opinion, FDA approval costs, along with research and
development cost should be capitalized. There should still be
restrictions, but these restrictions should be narrowed allowing
for more cost to be capitalized, thereby fueling the economy for
additional research and development leading to FDA approvals.
In many cases companies will not enter a research and
development/FDA project unless they are sure of success. They can
perform many tests - scientific and financial. Through preliminary
analysis a company can usually get a good indication of whether the
project will succeed or fail. Granted that this analysis is not
always 100 percent accurate, yet it is highly consistent and
provides a valid estimation of the overall picture of the project.
This provides support for the asset theory of the treatment of FDA
approval costs. Companies are not, for the most part, going to
enter a multi-million dollar project blind. For this reason I
recommend that companies put additional pressure on the FASB for a
change in their accounting policy regarding research and
development costs. In particular the FASB should address the area
of FDA approval costs.
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Another recommendation is to consider selling the product
under review in foreign countries who do not have as strict of
regulations as the United States does. This approach is
demonstrated by Biospherics, Inc. They decided to sell/release
drugs in other countries to generate the revenues needed for them
to gain FDA approval in the United States. This approach would be
useful after extensive testing of the drug has been completed so
that the possibility of harm to consumers using the product is
decreased.
A new approach was recommended by David E. and Paul E. Nix in
their article "Its Time to Change the Financial Accounting
Treatment of R&D Expenditures." In their approach they utilize a
contra-stockholder's equity account that is considered a permanent
account appearing on the balance sheet as a deduction from
stockholder's equity. They proposed to capitalize all research and
development expenditures as incurred during the year in this
contra-stockholder's equity account (unless the expenditures had
absolutely no future benefits in which case they would be expensed
immediately) . At year-end, a fixed percent of the remaining
balance in the contra account from prior years research and
development expenditures would be expensed for the current year.
This could result in a greater emphasis on research and
development, and even FDA approval, of products because none of the
current years research and development expenses would be reported
on this years financial statements.
According to the authors of the article, "the advantages of
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APPENDIX A
R & D ACTIVITIES
a) Laboratory research aimed at
discovery of new knowledge.
b) Searching for applications
of new research findings.
c) Conceptual formulation and
design of possible product or
process alternatives.
d) Testing in search for or
evaluation of product or
process alternatives.
e) Modification of the design
of a product or process.
f) Design, construction, and
testing of pre-production
prototypes and models.
g) Design of tools, jigs,
molds, and dies involving new
technology.
h) Design, construction, and











(from Kieso and Weygandt 608)
ACTIVITIES NOT CONSIDERED R & D
a) Engineering follow-through
in any early phase of
commercial production.





d) Routine, on-going efforts to
refine, enrich, or improve the
qualities of an existing
product.
e) Adaptation of an existing
capability to a particular
requirement or customer's need.
f) Periodic design changes to
existing products.
g) Routine design of tools,
jigs, molds, and dies.
h) Activity, including design
and construction engineering
related to the construction,
relocation, rearrangement, or
start-up of facilities or
equipment.




COMPANY NAME FDA COSTS REASON FOR TREATMENT
MEDCO RESEARCH EXPENSE UNABLE TO ESTIMATE FUTURE
BENEFITS
BARR EXPENSE UNABLE TO ESTIMATE FUTURE
LABORATORIES BENEFITS
HELIX BIOCORE EXPENSE ABLE TO ESTIMATE FUTURE
BENEFITS - CHOOSE TO EXPENSE
GULL EXPENSE UNABLE TO ESTIMATE FUTURELABORATORIES BENEFITS
STAAR SURGICAL EXPENSE UNABLE TO ESTIMATE FUTURE
BENEFITS
VISX EXPENSE UNABLE TO ESTIMATE FUTURE
BENEFITS
K V EXPENSE UNABLE TO ESTIMATE FUTURE
PHARMACEUTICAL BENEFITS
A L LABORATORIES EXPENSE UNABLE TO ESTIMATE FUTURE
BENEFITS
DOW CORNING EXPENSE UNABLE TO ESTIMATE FUTURE
BENEFITS
BIOPHAMACEUTICS EXPENSE UNABLE TO ESTIMATE FUTURE
BENEFITS
PHARMACEUTICAL EXPENSE UNABLE TO ESTIMATE FUTURERESOURCES BENEFITS
HOUSTON BIOTECH EXPENSE UNABLE TO ESTIMATE FUTURE
BENEFITS
HALSEY DRUG EXPENSE UNABLE TO ESTIMATE FUTURE
BENEFITS
BIOSPERICS EXPENSE UNABLE TO ESTIMATE FUTURE
BENEFITS

















BARR LABORATORIES, INC. AND SUBSIDIARIES
Consolidated Statements of Operations
Years ended June 30, 1992, 1991 and 1990
1992 1991 1990
Net sales (including sales to related
parties of $2,842,000 in 1992,
$1,938,000 in 1991 and $1,165,000
in 1990) (note 8)
Costs and expenses:






Other expense (income), net (note
10)
Earnings (loss) before income tax
expense (benefit)

















(e) Research and Development-Research and development costs, which consists
principally of product development costs, are charged to operations as
incurred.
(12) Other Matters-Food and Drug Administration (FDA) Litigation-After
completion of lengthy inspections of the Company's facilities in the fall of
1991 and again in the spring of 1992, the FDA determined that the Company was
not in compliance with current good manufacturing practice regulations (cGMP).
Upon learning of the FDA's position, the Company vigorously disputed the
findings because it believed that it was in substantial compliance with all
applicable regulations. Furthermore, the Company did not believe that the FDA
had the right to impose certain sanctions which are imposed automatically when
a company is deemed to be out of compliance with cGMP regulations. Although the
parties met numerous times to discuss the issues raised by the FDA and the
Company, those discussions were not fruitful because of the insistence by the
FDA that the Company agree at the outset to a consent decree which would have
caused the Company to cease all operations until such time as the alleged
deficiencies had been remedied to the FDA's satisfaction.
When it became clear that the Company and the FDA would not be able to
negotiate an end to their dispute, the Company undertook several actions.
First, in an effort to reach a swift settlement with the FDA and address its
regulatory and compliance issues, the Company temporarily reduced its product
line in April 1992. This reduction resulted in the suspension of the marketing
of a significant number of the Company's products. The Company believes that
all of its products, including those that were suspended, are safe and
effective for their intended use and conform to all applicable pharmaceutical
industry standards.
Second, in April 1992, the Company commenced an action in Federal District
Court in Newark, New Jersey (the Barr Action) seeking judicial clarification of
Barr's cGMP obligations and an injunction preventing the FDA from enforcing
ambiguous and shifting interpretations of the cGMP regulations. In addition,
the Company is seeking a judicial declaration that the FDA's Alert List and the
corresponding sanctions imposed upon the Company by the FDA associated with the
Alert List are illegal. The Company has moved for a preliminary injunction













a result of being included on the Alert List.
As of the date hereof, the cases are ongoing and,
currently available, it is not possible to determine
these actions on the Company's financial position or
based on the information
the possible effect of
results of operations.
PRESIDENT'S LETTER:
(FROM ANNUAL REPORT TO SHAREHOLDERS)
DEAR FELLOW SHAREHOLDER:
Optimism is high at the Company for a number of reasons. First, the
Company is poised to take advantage of new opportunities emerging in the
generic marketplace. Because of FDA's new interpretation of old regulations
and the increasing costs of regulatory compliance, many of our traditional
competitors are being forced to close their doors. FDA's actions have not
only reduced the number of competitors but also ensured that the new generic
marketplace will remain small. Barr Laboratories is far ahead of its
remaining competitors vis-a-vis these "new" regulations. This, combined with
our production capacity and ability to produce high quality pharmaceuticals,
provides the Company with an enormous strategic advantage.
Secondly, the Company continues to develop new products. Our research
and development activities, while having slowed during the dispute with FDA,
will be back in full operation shortly. In addition, the Company is
currently awaiting approval from FDA to market a significant number of new
products. Although it is not possible to predict when these new approvals
will be granted to FDA, we are optimistic that following the resolution of
the legal proceedings between Barr and FDA, approvals for these new
applications will be forthcoming.
Lastly, as shareholders of Barr Laboratories, Inc., you can be proud of
the effort and commitment of our highly skilled work force. Their efforts,
not only in production, scientific and marketing achievements, but those
required during our ongoing dispute with FDA, have truly been extraordinary.
Research and development expenses for the fiscal year ended June 30, 1992
were $7,436,027, compared to $5,908,793 for the comparable period last year.
This increase of 25.8% is primarily attributable to increases in salaries. The
Company also increased staff and incurred additional regulatory compliance
expenses.
Research and development expenses were $5,908,793 or 6.3% of net sales for
the fiscal year ended June 30, 1991 as compared to $3,965,961 or 5.6% of net
sales for the fiscal year ended June 30, 1990. This increase of 49.0% is
primarily attributed to an increase in outside clinical studies, salaries and
raw material consumed in the development of new products.
BIOPBARMACEUTICS IRC
BIOPHARMACEUTICS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
















Gain on sale of equipment
Settlement of claims with affiliate















Drug licensing receivable (Note 16)
Loss from continuing operations
Loss from discontinued operations
(Note 3)
Net loss














-NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
f. Research and development expenses-The Company expenses research and
development costs as incurred.
Note 2. Basis of Preparation-The Company has incurred losses in six
consecutive years, which have resulted in a decline in stockholders' equity to
a deficit of approximately $453,000 at September 30, 1992.
On January 10, 1992, the Company was approved to commence operations as a
drug repacker, after being shut-down for approximately two months in compliance
with a temporary restraining order obtained by the Food and Drug Administration
("FDA") on November 1, 1991. The Company is currently seeking approval to
resume its manufacturing operations pursuant to an amended decree of permanent
injunction for alleged current good manufacturing practice deficiencies in its
drug manufacturing activities. Upon achieving this approval, the Company
intends to develop prescription products which do not require the approval of
the FDA, but carry higher profit margins than the over-the-counter products
previously sold by the Company. In addition, the Company plans to apply for FDA
approval of prescription drugs, which both require bioavailability studies or
do not require bioavailability studies.
BIOSPHERICS IRC
Consolidated Statements of Operations
Years ended December 31
Revenues
Contract revenues (Note 1)
Product and process sales
Total revenues
Costs and Expenses Operating Expenses
Direct costs and operating expenses,
excluding depreciation and
amortization








Other income (Note 11)
Interest expense
Income before income taxes and
extraordinary item
Provision for income taxes (Note 6)
Income before extraordinary item
Extraordinary item (Note 9)
Net Income























































ITEM 6. Management's Discussion of Financial Condition and Results of Operations
The BioTech Programs Unit generated revenues from royalties and sales of its
specialty chemicals of $149,000 in 1992, compared with $467,000 in 1991.
Research and Development expenditures were $270,000 and $250,000 for 1992 and
1991, respectively. The spending in 1992 was related to new studies in support
of its patented nonfattening sugar, D-tagatose, and safe-for-humans pesticide.
There are a number of factors that could potentially have a significant
impact on future earnings and the financial condition of the Company. As
previously discussed in Item 1, the Company is continuing its effort to bring D-
tagatose and the safe-for-humans pesticide to market. Research and Development
costs are expected to increase in 1993 as part of this effort. Full-scale
toxicity test on D-tagatose have begun, which, upon completion, should clear
the way for sales of the product overseas. Profits generated from these sales
will be utilized to fund the testing necessary to obtain FDA approval, thus
opening the U.S. market.
Cash generated from operations will continue to be utilized to fund the
ongoing research and development effort. An example of this was the Company's
ability to fund the full-scale toxicology test for D-tagatose in the first
quarter of 1993. Consistent with the Company's policy, excess profits will be




(in millions of dollars
Year ended December 31
OF OPERATIONS AND RETAINED EARNINGS
except per share amounts)
NET SALES
OPERATING COSTS AND EXPENSES:
Manufacturing cost of sales












Interest income, currency gains
(losses) and other, net
Interest expense
INCOME BEFORE INCOME TAXES
Income taxes
Minority interests' share in income
INCOME BEFORE CUMULATIVE EFFECTS OF
CHANGES IN ACCOUNTING PRINCIPLES
(1992 - $11.36 per share;
1991 - $54.64 per share;
1990 - $68.44 per share)
NET INCOME (LOSS) (1992 - $(28.80)
per share; 1991 - $61.16 per share;
1990 - $68.44 per share) -72.0









integral part of these
FINANCIAL FOOTNOTES:
-NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Research and Development Costs-Research and development costs are charged
to operations when incurred and are included in manufacturing cost of sales.
These costs totalled $161.2 in 1992, $148.7 in 1991 and $139.8 in 1990.
NOTE 2 - CONTINGENCIES-Breast Implant Business-Prior to January 6, 1992,
the Company, directly and through its wholly-owned subsidiary, Dow Corning
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Wright Corporation, was engaged in the manufacture and sale of silicone gel
breast implants. As part of a process initiated in 1991 of review by the United
States Food and Drug Administration (FDA) of Premarket Approval Applications
(PMAA) for silicone gel breast implants, on January 6, 1992 the FDA asked
breast implant producers and medical practitioners to halt the sale and use of
silicone gel breast implants, pending further review of the safety and
effectiveness of such devices, and the Company voluntarily suspended shipments
of implants. Subsequently, the Company announced that it would not resume the
production or sale of silicone gel breast implants and that it would withdraw
its PMAA for silicone gel breast implants from consideration by the FDA.
GULL LABORATORIES IRC
Gull Laboratories, Inc
Consolidated Statements of Operations















Total other income (expense)
Income from continuing operations
before provision for income taxes
Income tax provision (Note 7)
Income from continuing operations
Discontinued operations - loss of
USANA, Inc. to be spun off (net
of income tax benefit) (Notes 2
and 7)
Net income (loss)
Earnings (loss) per share:
Continuing operations
Discontinued operations
Earnings per common and common



































ITEMS 6: MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATIONS
Research and development costs increased 20% in 1992 from $582,515 to
$696,561. In 1992 the Company's research and development efforts decreased as
the new ELISA product line was transferred out of research and development to
production. During 1992 the Company renewed its research and development
efforts to find new test to supplement its existing product line.
Research & development costs decreased 46% in 1991 to $582,515 compared
with $1,070,055 in 1990. This decreased is primarily due to the successful
completion of development of the Company's new ELISA product line and the
transfer of many of the employees working on the development project to product
manufacturing.
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HALSEY DRUG CO IHC
Halsey Drug Co., Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF EARNINGS
Year ended December 31
Net sales (Note A)
Cost of goods sold
Gross profit
Research and development
Selling, general and administrative
expenses




Earnings before income taxes and
minority interest
Provision for income taxes (Notes A
and F)
Earnings before minority interest
Minority interest in net loss
(earnings) of subsidiaries (Note B)
NET EARNINGS
Earnings per common share (Note A)





















































The accompanying notes are an integral part of these statements.
MANAGEMENT DISCUSSION:
Item 7. Management's Discussion and Analysis of Financial Condition and
Results of Operations.
The Company's continued increased sales are linked to expanding sales of
existing products as no new products were introduced by the Company in 1992,
although Houba received a supplemental approval for one new product. The
Company's increase in sales is a result of increased sales of previously
existing products through improved marketing and manufacturing and an expansion
of the Company's customer base.
Research and Development Expenses Research and development expenses for
fiscal years 1992, 1991 and 1990 were approximately $1,090,237, $783,000 and
$592,000, respectively, which, expressed as a percentage of sales, were 2.2%,
2.1% and 2.3%, respectively. The Company's research and development efforts
during 1992 were predominantly directed at the development of Biotin and
Zidovudine (AZT) raw materials at the Indiana facility. The Company has and in
the future will, to the extent possible, continue to take an aggressive
position in the development of new products coming off of patent protection or
expected to become available in the near future. The Company also has chemical
products at various stages of development and production.
HELIX BIOCORE IHC
PRESIDENT'S LETTER:
(FROM ANNUAL REPORT TO SHAREHOLDERS)
To Our Shareholders and Friends:









the heart valve market. As you may know, our management team and employees
have extensive experience in the cardiovascular field, many having been
previously involved in the development of implantable devices, including
heart valves. This has allowed us to develop a new heart valve with a new
pivot concept which is designed to reduce thromboembolism and thrombosis;
problems long recognized as the scourge of heart valves. Under a development
agreement with CarboMedics, Inc., the world's largest and most experienced
manufacturer of heart valve components, we will develop, manufacture and
market our new open pivot, bileaflet, pyrolytic carbon heart valve. The
design, which is protected by two issued U.s. patents and six issued overseas
patents together with additional patent applications, is being prepared for
our first human implant which we anticipated will occur in Europe in the
first half of 1992.
During 1991, we received encouragement and comments from the medical
community, which confirms our belief that we will succeed in the heart valve
market. Let us review some of those thoughts:
Today, estimates are that the world market for heart valves is $410
million. Our initial commercial introduction into the U.s. market will be
limited, as we must conduct clinical trials and seek FDA regulatory approval.
In the international market, however, we feel that we will be able to
introduce our valve and begin to generate revenues in 1992.
MANAGEMENT DISCUSSION:
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
Research, development and engineering expenses related to the heart valve
operations increased by 96% from 1990 ~o 1991. The increase resulted from a
full year's development under the heart valve program which the Company
commenced in November 1990. The expenses incurred in 1991 and 1990 included
$404,331 and $383,000, respectively, in payments to outside vendors for
development work related to the ATS Medical valve. The Company expects that
research, development and engineering expenses will increase substantially
during 1992 as the Company continues testing of the Valve and meets additional
milestone for payments to outside vendors.
FINANCIAL STATEMENT TEXT:
NA; Income Statement Data provided only for NYSE, AMEX, NASD and Fortune
1,000 companies.
FINANCIAL FOOTNOTES:




Year Ended December 31
REVENUES:
Research and development contracts:





















part of these financial statements.
proprietary
General and administrative
Writedown of capitalized construction
costs
Total costs and expenses
INCOME (LOSS), before income taxes
and extraordinary item
Income taxes
INCOME (LOSS), before extraordinary
item
.
EXTRAORDINARY ITEM, utilization of
net operating loss carryforward
NET INCOME (LOSS)
The accompanying notes are an integral
FINANCIAL FOOTNOTES:
--(1) Organization-HBI is a biotechnology company engaged in
the development of pharmaceutical products to treat or prevent a variety of
common ophthalmic and neurological diseases and disorders, with a primary focus
in ophthalmology. The principal objective of the Company is to 'develop
biopharmaceutical products to treat conditions for which no effective
pharmaceutical treatment is currently available or for which such products may
provide advantages over existing treatments. The Company's most advanced
product is an immunotoxin for the prevention of secondary cataract (the "4197X-
RA Immunotoxin").
Until April 30, 1992, substantially all of the Company's research and
development activities related to contract research performed for Houston
Biotech Partners, L.P. (the "Partnership"), a research and development
partnership.
Revenues resulting from the 4197X-RA Immunotoxin had not commenced as of
December 31, 1992, and are not expected to do so, if at all, for at least
several years. Development of pharmaceutical products takes many years and
involves a high degree of risk and uncertainty. There can be no assurance that
any revenues will ever be generated from development efforts. In addition, it
is probable that current funds available to invest in research and development
will be insufficient to complete the 4197X-RA Immunotoxin to commercialization.
Contract Research Revenues-Contract research revenues consist of
nonrefundable amounts earned under contractual agreements to perform research
and development of specific scientific projects and are recognized as revenues
as the research is performed or as milestones are achieved (see Note 3). As a
result of the Combination, contract research is no longer conducted on behalf
of the Partnership, and therefore contract research revenues related to
contract research on behalf of the Partnership were no longer recognized.
Research and Development Costs-HBI performed contract research on behalf of
the Partnership through April 30, 1992, as well as its own independent
proprietary research. Research and development costs are expensed when
incurred. These costs consist of direct costs associated with specific projects
including costs associated with the operation of laboratories performing such
research, and in the case of contract research, an allocation of general and
administrative costs associated with administering these activities. As a
result of the Combination, contract research is no longer conducted on behalf
of the Partnership, and therefore HBI no longer allocated general and
administrative costs. See Note 10.
MANAGEMENT DISCUSSION:
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
The following discussion and analysis should be read in conjunction with
the Financial Statements and related notes contained elsewhere herein.
Product Development Development of biopharmaceutical products involves a
high degree of risk and uncertainty and requires a large investment of cash and
technical resources before commercialization. The Company's realization of its
investment in its research and development efforts will not occur unless and
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until regulatory approval to market is obtained and profits are generated at a
future date. The FDA requires compliance with strict regulatory procedures
before it will grant approval for a pharmaceutical product to be marketed in
the United States. These regulatory procedures require, among other things:
(i) preclinical development and filing an IND with the FDA, (ii) Phase I human
clinical trials to test safety, which normally take from one to three years,
(iii) Phase II and III human clinical trials to confirm the results of Phase I
safety studies, prove efficacy and observe any low-incidence adverse effects,
which normally take from two to three years each, and (iv) filing a PLA with
the FDA containing the results of the human clinical trials for review and
approval by the FDA, a process which normally takes approximately two to three
years. There is no assurance that FDA approval of the 4197X-RA Immunotoxin or
any product candidate can be obtained within these time frames, if at all.
The Company filed the IND with respect to the 4197X-RA Immunotoxin in
August 1990, filed a Phase I report with the FDA in January 1992 and commenced
a Phase I/II human clinical study in April 1992. Primarily becaus~ of an
unacceptable level of patient enrollment by doctors recruited by the CRO
engaged by the Company for the purpose, HBI closed its initial investigational
site and terminated its relationship with the CRO performing the study. HBI
has redesigned the study to facilitate patient recruiting and simplify study
execution without compromising patient safety. Patient enrollment began in
March 1993. See "Business-Secondary Cataract-Human Clinical Trials."
Operating expenses for the year ended December 31, 1992 were $3,758,088, an
18% increase from $3,169,536 incurred in the same period in 1991. This increase
was due to increased research and development on Company projects other than th
4197X-RA Immunotoxin and the writedown of capitalized construction costs.
MEDca RESEARCH INC
Medco Research, Inc.
Consolidated Statements of Operations
Year Ended August 31
Revenues:








Royalty expense (Note 5)
Research and development costs
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(FROM ANNUAL REPORT TO SHAREHOLDERS)
Dear Shareholder:
Medco remains dedicated to a strategy of identifying and licensing
additional pharmaceutical products of promising potential.
Approval of Adenoscan(R) by the Health Protection Branch of Canada's
Health and Welfare Department for marketing in Canada, with commercialization
to commence following the grant of an export license by the U.S. Food and
Drug Administration to Medco's licensee, Fujisawa USA, Inc.
Continued clinical trials of adenosine (MEDR 640) as a cardioprotectant
in patients who have suffered a heart attack, and initiation of such trials
in patients who are undergoing coronary artery bypass surgery
Commencement of Phase II clinical trials of IPPA, a nuclear cardiac
diagnostic agent
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Commencement of Phase I clinical trials of adenosine triphosphate (ATP),
which is being studied for treatment of cancer and cancer-related cachexia
(weight loss and bOdy-wasting syndrome)
Commencement of multicenter clinical trials for the oral antiarrhythmic
drug, NAPA(R), for the treatment of two types of arrhythmia in the atria
(upper chambers of the heart)
Commencement of development of Bidil(TM) as a vasodilator therapeutic for
patients suffering from congestive heart failure.
With an array of products in the late stages of clinical development,
principally for the treatment of cardiovascular diseases and cancer, we
believe Medco is moving closer to the point of commercial breakthrough.
We are disappointed that the Food and Drug Administration has not yet
approved Adenoscan(R) in the United States. Our progress has been delayed by
issues arising from the drug-manufacturing activities of Lyphomed Inc., which
was subsequently acquired by Fujisawa USA, our Adenoscan(R) manufacturing and
marketing partner. Fujisawa USA has advised Medco that it is working
diligently to satisfy any Food and Drug Administration concerns with respect
to the manufacture of its products.
MANAGEMENT DISCUSSION:
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND
FINANCIAL CONDITION
During fiscal year 1992, the Company's principal activities consisted of
the continued development of, and regulatory submissions for, its adenosine
products and the identification and acquisition of new products. In November
1991, the Company entered into an exclusive worldwide license agreement to
research, develop, manufacture and market Bidil for patients with CHF. In
April 1992, the Company entered into an agreement for the development and
marketing of IPPA in the United States. The Company's research and development
expenses increased substantially in fiscal year 1992 due to acceleration or
initiation of clinical trials for the development of MEDR 640, NAPA, ATP, Bidil
and IPPA.
During fiscal year 1991, the Company focused on filing New Drug Submission
applications to the Canadian Health Protection Branch (HPB) for Adenocard and
Adenoscan and on investigating potential new indications for adenosine.
Attention was also directed to recruiting senior staff personnel and licensing
new products for development by the Company. During fiscal year 1991, the
Company entered into an exclusive worldwide license agreement to research,
develop, manufacture and market ATP for use in cancer treatment.
Research and development costs increased seven-fold, from $298,286 to
$2,160,634, reflecting the Company's planned acceleration of research and
development activities, including contract manufacturing and clinical research
contracts, for NAPA, ATP, Bidil, IPPA, MEDR 640 and bethanidine sulfate, and
salary and overhead expenses directly related thereto. Research and development
costs are expected to continue to be substantially higher than those incurred
in prior years.
Research and development costs decreased from $438,023 to $298,286, a
decrease of 32%, primarily due to a substantial reduction in direct clinical
trial expenses associated with the completion of the development of Adenoscan,
for which an NDA was submitted to the FDA in February 1990. Salary and overhead
expenses directly related to research and development activities remained
virtually unchanged as the Company focused on (a) preparing plans for the
clinical development of several of its other products; (b) conducting early
stage clinical trials of selected adenosine products; and (c) monitoring and
updating additional clinical data relating to Adenoscan, none of which required
significant direct clinical trial expense. Research and development costs are
expected to increase substantially during fiscal year 1992 from fiscal year
1991 as the Company begins or accelerates clinical trials for MEDR 640, NAPA,
ATP, Bidil, IPPA, bethanidine sulfate, MEDR 340 and MEDR 240.
The Company is continuing with its planned acceleration of the development
of its products by significantly increasing its research and development
expenditures for preclinical development activities and clinical testing of its
products and the recruitment of additional scientific, administrative and
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support personnel. Accordingly, until such time as Adenoscan is approved by
the FDA and marketing of this products commences, the acceleration of research
and development will have a material affect of the Company's earnings and could
result in reduced net income or net losses in the future. The Company is also
exploring the possibility of developing within the next several years a
limited, specialized sales force for the marketing of certain of its products,
which would require significant additional expenditures. The Company believes
that it has more than sufficient cash reserves to fund its current operations,
including the accelerated development of its products, the recruitment of
additional personnel and the development of a limited sales force as described
above.
Except for Adenocard, which has been approved and marketed in the United
States, the United Kingdom and Switzerland, the Company will not generate
revenues from its products until it receives approval from the FDA or
corresponding agencies in other countries to market these products. In October
1992 the Canadian Health Protection Branch ("HPB") approved the marketing of
Adenoscan in Canada. Commercialization of this drug in that country will not
commence until the FDA grants an export license for the manufacture of this
product by Fujisawa USA, which must resolve certain of the manufacturing issues
with the FDA referred to below the license will be granted. The FDA's review
of the Adenoscan NDA has been delayed as the result of certain manufacturing
issues raised by the FDA with respect to various products including Adenoscan
manufactured by Lyphomed, Inc. (the Company's original manufacturing and
marketing partner for adenosine products which was acquired by Fujisawa USA in
April 1990.) Fujisawa has advised the Company that it has successfully
completed its internal validity assessment of the Adenoscan manufacturing data,
and that it is working diligently with the FDA to resolve the outstanding
issues with the FDA so that the FDA can then complete its review of the NDA.
It is possible, however, that delays in resolving these issues, including those
relating to other Fujisawa products, could affect the timing of any FDA
approval of the Adenoscan NDA.
As with any new drug, including those currently under development by the
Company, the Company cannot predict the research results or the timing of any
potential marketing approval, nor can assurances be given that the FDA or
corresponding agencies in other countries will approve any of the Company's
products.
FINANCIAL FOOTNOTES:
5. Patent, Trademark and Distribution Rights-The Company is engaged in the
development of new prescription drugs in pursuit of obtaining governmental
marketing approvals in the United States and other countries. The Company
acquires exclusive rights to develop and market various drugs from third
parties, including related patents and trademarks (where applicable), and
develops drugs and seeks patents and trademarks for its products on a
proprietary basis. The costs of acquiring rights from third parties and major
costs associated with the perfection and protection of patents and trademarks
are capitalized by the Company. Agreements under which the Company acquires
such rights from third parties generally require the Company to finance the
costs of clinical trials and the filing of New Drug Applications (NDAs) with
the United States Food and Drug Administration (FDA) and, in some instances,
comparable applications with appropriate regulatory agencies in other
countries. The Company is also typically required to pay royalties to such
third parties based on sales of the applicable approved drugs and, pursuant to
certain agreements and under certain circumstances, the Company is obligated to
make advance royalty payments to such third parties.
In October 1989, the Company received FDA approval to market Adenocard(R)
in the United States. The Company entered into agreements with Fujisawa USA,
























part of these statements.
CONSOLIDATED STATEMENTS OF OPERATIONS AND RETAINED EARNINGS (DEFICIT)





Cost of goods sold
Product development
Selling, general and administrative
Interest
Settlements of legal proceedings
Regulatory review costs, recalls
and other matters
Income (loss) from continuing
operations before income taxes
Provision (credit) for income taxes




Estimated gain (loss) on disposition
Income (loss) before extraordinary
item
Extraordinary item--tax benefit
of utilization of net operating
loss carryforward
Net income (loss)
The accompanying notes are an integral
FINANCIAL FOOTNOTES:
(SOURCE 10-K)
NOTES TO FINANCIAL STATEMENTS
The Company operates in one business segment, the manufacture and
distribution of generic pharmaceuticals. Products are marketed principally in
oral solid (tablet and capsule) form.
Product Development:-Product development expenses consist primarily of
research and development costs. All such costs are expensed as incurred.
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MANAGEMENT DISCUSSION:
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
Operating Expenses Product Development Product development costs for the
year ended October 3, 1992 of $978,000 decreased or 37% from fiscal 1991 costs.
The decrease was due to management's decision during the prior year to suspend
all product development efforts relating to the oral liquid and topical product
lines, as well as to curtail efforts relating to the oral solid product line.
Management has decided to revitalize its product development efforts in fiscal
1993 relating to the oral solid product line, including hiring additional
personnel, purchasing raw material and contracting with outside laboratories to
conduct biostudies and, accordingly, expects related costs to increase
substantially from current levels. In addition, the Company is actively
pursuing alternatives to supplement its internal product development efforts,
such as joint ventures, licensing agreements and the reintroduction of
additional products from the distribution moratorium (see "Results of
Operations--Sales" above). There can be no assurance that these efforts will
be successful.
FDA has advised Par that FDA will not review new product applications
submitted by Par, nor will Par be eligible to receive new drug application
approvals, before the conclusion of the validity assessment process (see "Notes
to Financial Statements--Contingencies and Other Matters--Validity Assessments
by FDA"). The Company has been taking, and intends to continue to take, any
necessary steps to conclude the validity assessment process. Management is
unable to predict the impact that the validity assessment process will have on
future results of operations.
Product development costs in fiscal 1991 of $1,546,000 decreased $402,000 or
21% from $1,948,000 in the fiscal 1990 year. Such decrease was due to
management's decision during fiscal 1991 to suspend all product development
efforts relating to the oral liquid and topical products lines, as well as
curtail efforts relating to the oral solid product line.
Although the major portion of the regulatory audits being conducted by the
Company's outside consultant is complete, the Company is unable to predict the
length of time that it will take for the balance of the regulatory reviews and
audits to be concluded, nor is it able to predict the extent or magnitude of
any additional corrective actions that may be necessary due to review or audit
findings or the results of FDA's validity assessments (see "Notes to Financial
Statements--Contingencies and Other Matters--Validity Assessments by FDA").
Accordingly, it is possible that the Company will incur additional costs to be
reported under this item, and such costs may be material.
STAAR SURGICAL CO
FINANCIAL STATEMENT TEXT:
NA; Income Statement Data should be available by 07/26/93.
FINANCIAL FOOTNOTES:
NA; Data provided only for NYSE, AMEX and Fortune 1,00 companies.
MANAGEMENT DISCUSSION:
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
Overview Since its inception in 1992, the Company has directed its efforts
to providing products, systems, procedures, and technology that restore vision
through small incision cataract surgery, save vision through glaucoma surgery,
and now provide better vision through implantable contact lenses.
The new management team ef fected a turn-around in the Company by: 1)
obtaining pre-market approval from the FDA in September 1991 for the unrestricted
sale in the United States of the Company's ELASTIC(tm) and ELASTIMIDE(tm)
foldable IOL's, 2) obtaining approvals to market the same products in most other
countries, 3) resolving and settling significantly all of the Company's
substantial and costly litigation, 4) licensing the Company's technology to
generate approximately $11.6 million in non-dilutive capital to eliminate the
Company's capital deficiency and to provide cash flow for various corporate
purposes until such time as the Company generates a profit, and 5) raising
capital from private placements of the Company's securities, also for the purpose
of eliminating the Company's capital
deficiency and to provide cash flow for various corporate purposes pending
profitability.
This significant sales growth resulted primarily from increased sales of the
Company's foldable IOLs which were approved by the FDA in September 1991 for
marketing and sales in the United States. The sales growth when considering
only foldable IOL's was over 300%.
Research and Development Research and Development costs nominally
increased 13.4% over the 1991 level. The Company's R&D efforts have been
focused on reducing the cost to manufacture current products; making current
products easier to use, making current products less invasive during surgery,
and developing new products for better vision care. The Company has reduced
its costs of manufacturing, and has designed and introduced products that are
easier to use than any other competitive products in the marketplace. As a
direct result of these R&D efforts, the Company has recently announced two new


































and the implantable contract lens (ICL) which is aimed at the general vision
care marketplace. All of these technological advancements should enhance the
future sales growth of the Company. The Company continues to demonstrate its
technological leadership in vision care marketplace.
Research and Development Research and development expenses
approximately 8.3% for 1991 compared to 1990. The decrease was
to the fact that most of the research required for FDA approval





UNIVERSITY PATENTS, INC. AND SUBSIDIARIES
Consolidated Statements of Operations




General and administrative expenses,
including costs of technology
management business of which
$60,000, $89,000 and $200,000
were paid to related parties
Costs of computer-based education
services, including $92,000,
$143,000 and $120,000 paid to
related parties
Reversal of accrued rent
liability
Operating loss
Gain on issuance of shares by
subsidiary
Net gain on sale of investments
Interest income
Interest expense
Losses related to equity method
affiliates
Loss from continuing operations
before income taxes and minority
interest
Provision (benefit) for income taxes
Loss from continuing operations
before minority interest
Minority interest in losses of
consolidated subsidiary
Loss from continuing operations
Discontinued operations:















Income and Expenses-Expenditures made in connection with evaluating the
marketability of inventions, pursuing patent applications, licensing patents
and patent litigation are charged to operations as incurred.
PRESIDENT'S LETTER:
















Subsequent to the end of fiscal 1992, University Patents made a major
strategic move. It returned to the university-based technology transfer
business and now actively seeks new university clients whose technologies it
will attempt to commercialize. This comes at a time when corporate research
and development is on the wane and universities continue to maintain their
preeminence as America's greatest source of basic research.
The acquisition of 80% of Lehigh University's technology unit,
Competitive Technologies, Inc. (CTI) in October, 1992, was the culmination of
a strong corporate inclination to return to what University Patents does best
evaluate, license and commercialize inventions arising fro university
research. When UPI sold its technology transfer business in 1988, the
environment was much different -- the entrepreneurial spirit was sweeping
campus administrations and industry was investing heavily in R&D. But that
climate has now changed, leading UPI to believe that the time is right to
reenter the field, but with a different set of rules and priorities.
UPI's previous modus operandi was to work with universities on a totally
contingent basis, with UPI bearing all the expenses of evaluating, patenting
technologies and searching for licensees to further develop the technologies
and bring them to market. With the purchase of CTI, UPI has created a
partnership with Lehigh University for the management of the university's new
inventions. CTI has a five-year contract (subject to conditions) under which
the university pays an annual fee to CTI and provides facilities and
resources to help defray some of the costs associated with the
commercialization process. At the same time, CTI retains a healthy interest
in the successful conclusion of licenses obtained on those technologies. The
Lehigh-UPI partnership creates an environment that reduces operating costs
and risks for both parties. UPI plans to use the CTI partnership as a model
for contracts it hopes to strike with other universities and Federal
agencies/labs with technology to offer. CTI has also brought to UPI a number
of government relationships with groups such as the National Science
Foundation and the U.S. Department of Defense under revenue-producing tech
transfer and collaborative R&D management contracts.
An important UPI technology - the anti-photoagingproduct Retin-A - is
now before the Food and Drug Administration. Once FDA approval is granted to
Johnson & Johnson, its producer, and sales volume begins to build, we except
that this product will generate significant royalty income for our Company.
VISX IRC
VISX, Incorporated and Subsidiaries
ONSOLIDATED STATEMENTS OF OPERATIONS
For the years ended December 31, 1992, 1991 and 1990
(In thousands, except per share data)
Revenues:
Product sales
Product sales to Alcon, a related
party
Development revenues




Marketing, general and administrative
Research, development and regulatory
Purchased research and development



















Net Sales 41,368,435 34,457,148 30,147,069Investment Income 650,171 663,195 1,440,791Total Revenues 42,018,606 35,120,343 31,547,860Costs and Expenses:
Manufacturing Costs 27,808,368 23,959,032 22,152,713Research and development 4,880,180 4,218,469 3,926,743Selling and administrative 8,468,429 7,036,148 5,617,371Interest expense 1,009,785 1,329,255 900,288Total Costs and Expenses 42,166,762 36,543,904 32,597,115Loss before income taxes
-148,156
-1,423,561





would require treatment for both nearsightedness and astigmatism in order to
achieve optimum visual acuity and to eliminate the need for corrective
lenses.
MANAGEMENT DISCUSSION:
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
Research, development and regulatory expenses increased $2,781,000, or
104%, in 1992 compared to 1991. This increase reflects the Company's continued
investment in research, development and regulatory personnel, increases in
material costs, increases in regulatory expenses associated with the FDA
studies and the addition of Questek's research and development organization.
Research, development and regulatory expenses decreased $1,808,000, or 40%, in
1991, compared to the prior year. This decrease reflects reductions in
research, development and regulatory personnel consultants and product
development material expenses resulting from the consolidation of operations
after the Merger.
K V PHARMACEUTICALS
K V PHARMACEUTICAL COMPANY AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
For the Years Ended March 31, 1992, 1991, and 1990
During fiscal 1992, research and development costs increased to $4,880,180,
an increase of 16% over the prior year. As a percent of revenue, these costs
remained at 12%. Research and development expenses were $4,219,469 in fiscal
1991 and $3,926,743 in fiscal 1990. These costs are linked directly to the
expansion of the Company's drug delivery technologies and new product
development. The Company expects these expenditures to continue at a relatively
high level related to proprietary new products.
Compared to a new drug entity, which is a drug molecule that has never been
approved by the FDA or commercially marketed, an Improved Drug Entity(TM) is a
patented or off-parent drug (already approved by the FDA for marketing in its
original form) which has been converted by a K V drug delivery system technology
to have differentiated and improved benefits.
The Company expects to continue a relatively high level of expenditures and
investment for research, clinical, and regulatory efforts relating to development
and commercialization of proprietary new and Improved Drug Entities(TM) and their
approval for marketing. Delays in FDA approvals have been experienced industry-
wide by pharmaceutical companies in general and there can be no assurance such
delays will not continue.
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A. L. LABORATORIES, INC.
















CONSOLIDATED STATEMENT OF INCOME
(In thousands)








Other income (expense), net
Income from continuing operations
Provision for income taxes
Income from continuing operations




Reasons for the decision included the delays experience by the Company in
obtaining drug approvals by the FDA, while maintaining an increased level of
expenses related to personnel, research, product development, and clinical
testing necessary to support regulatory submissions and approvals.
The development, manufacturing and marketing of the Company's products are
subject to regulation which includes inspections and controls over manufacturing
practices and procedures, requires approval to market products, and can result
in the recall of products and suspension of production. In the United States the
Food and Drug Administration(FDA), has imposed increasingly comprehensive
oversight and more stringent regulatory requirements on the pharmaceutical
industry, with the result of substantially increasing the cost of regulatory
compliance incurred in the production and marketing of pharmaceutical products.
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